Meropenem in the treatment of complicated skin and soft tissue infections by Fish, Douglas N
Therapeutics and Clinical Risk Management 2006:2(4) 401–415
© 2006 Dove Medical Press Limited. All rights reserved
401
REVIEW
Abstract: Meropenem is a broad-spectrum carbapenem antibiotic with excellent activity
against many pathogens associated with complicated skin and soft tissue infections (cSSTIs).
At least three studies have shown meropenem to have good clinical efficacy and to be well
tolerated in the treatment of cSSTIs. Two open-label studies compared meropenem 500 mg
every 8 hours (total evaluable n=146) with imipenem/cilastatin 500 mg every 6 hours (n=147).
Clinical efficacy rates in evaluable patients 7–14 days after end of treatment were similar,
92% and 100% in meropenem-treated groups versus 89% and 100% in groups receiving
imipenem/cilastatin. An additional prospective, randomized, double-blind study evaluated
meropenem 500 mg every 8 hours (261 evaluable patients) versus imipenem/cilastatin 500 mg
every 8 hours (287 patients). Clinical efficacy rates of meropenem and imipenem/cilastatin
7–28 days after end of treatment were 86.2% and 82.9%, respectively. Meropenem was well
tolerated in all studies. Carbapenems are currently recommended as appropriate for initial
treatment of certain cSSTIs such as those likely to involve mixed and/or multidrug-resistant
pathogens. Meropenem is an effective and safe alternative for monotherapy when used for
appropriate types of cSSTIs. Higher doses (ie, 1 g every 8 hours) should be considered for
treatment of cSSTIs in higher-risk patients where Pseudomonas aeruginosa is a suspected or
documented pathogen.
Keywords: meropenem, carbapenems, wound infection, diabetic foot, antibiotics, nosocomial
infection
Introduction
Skin and soft tissue infections (SSTIs) are very frequently encountered in clinical
practice and are one of the most common sites of bacterial infections (Nichols 1999;
Eron et al 2003; DiNubile and Lipsky 2004). These infections are also among the
most common indications for antibiotic therapy and hospital admissions in the US
(CDCP 2001). Complicated skin and soft tissue infections (cSSTIs) are those which
involve abnormal skin or wounds, occur in a compromised host, or require substantial
surgical intervention (DiNubile and Lipsky 2004). Because cSSTIs are by definition
more severe in nature and are often associated with complications such as bacteremia
and sepsis, patients with these infections are often hospitalized for management with
intravenous antibiotics (Nichols 1999; Swartz 2000; Eron et al 2003; Stevens et al
2005). Many cSSTIs are also nosocomial in origin; it has been estimated that these
infections are the most common nosocomial infection among surgical patients and
occur in approximately 2.6% of all operations (Wilson 2003).
Meropenem (Merrem
®, AstraZeneca Pharmaceuticals, Wilmington, Delaware,
USA) is a broad-spectrum antibacterial agent of the carbapenem class. Meropenem
has excellent activity against a broad range of bacteria including many Gram-positive
and Gram-negative pathogens, including many potentially resistant strains such as
Pseudomonas aeruginosa, as well as anaerobic organisms (Wiseman et al 1995;
Fish and Singletary 1997). Because cSSTIs often involve a diverse range of both
aerobic and anaerobic pathogens, meropenem was studied for the treatment of cSSTIs
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and was approved by the US Food and Drug Administration
(FDA) for this indication in May 2005. The purpose of this
article is to briefly review the clinical characteristics and
bacterial etiology of cSSTIs, discuss pharmacological and
clinical data pertaining to the use of meropenem for these
infections, and provide recommendations regarding the role
of meropenem in the treatment of cSSTIs.
Complicated skin and soft tissue
infections
Clinical characteristics
The majority of SSTIs are classified as uncomplicated
infections, ie, infections defined as involving only superficial
layers of the skin (epidermis, dermis, and subcutaneous
tissues) (Eron et al 2003; Stevens et al 2005). Uncomplicated
infections such as impetigo, erysipelas, simple abscesses,
and simple cellulitis are typically mild to moderate in
severity and easily treated with local care with or without
oral antibiotic therapy (Eron et al 2003; Raghavan and
Linden 2004; Stevens et al 2005). By contrast, cSSTIs
involve deeper skin structures such as fascia or muscle layers
and require surgical intervention for effective management
(Eron et al 2003; Fung et al 2003; DiNubile and Lipsky
2004). These complicated infections are often associated
with significant comorbidities such as diabetes mellitus,
peripheral vascular disease, critical illness, human
immunodeficiency virus (HIV) infection, and other
immunocompromised states such as malignancy or post-
transplantation (Nichols 1999; Swartz 2000; Fung et al 2003;
DiNubile and Lipsky 2004; Stevens et al 2005). Examples
of complicated infections include more complex cellulitis
and abscesses, perirectal abscesses, post-traumatic or
surgical site infections, myositis, necrotizing fasciitis, and
infected diabetic and vascular ischemic ulcers. These
infections can be challenging to effectively manage because
of the great diversity in pathophysiology, microbial etiology,
clinical manifestations, severity, and potential for additional
complications such as bacteremia, sepsis syndrome, and
organ dysfunction (Swartz 2000; Eron et al 2003; Lipsky et
al 2004; Stevens et al 2005).
The pathophysiology of cSSTIs is also significant in
terms of potential effects on antimicrobial efficacy. Since
the efficacy of antimicrobials depends on the ability to
achieve adequate concentrations at a particular site of
infection, good distribution to infected tissues is a key feature
of any agent. However, cSSTIs are commonly associated
with vascular insufficiency due to underlying comorbidities,
disruption of normal blood and lymphatic flows, and/or areas
of devitalized tissue, all of which may severely limit the
penetration of drugs to the site of bacterial infection. The
possibility of significantly decreased penetration of
antimicrobials to tissues involved in cSSTIs thus may
potentially lead to inadequate drug concentrations, clinical
and microbiological treatment failure, and the development
of resistance among bacterial pathogens. Successful
antimicrobial management of cSSTIs therefore depends on
the use of agents possessing the combination of good
intrinsic activity against potential pathogens and intrinsic
ability to distribute to tissues of the skin and skin structures,
plus use of relatively high doses which increase the
likelihood of sufficient tissue penetration.
Bacterial etiology
Complicated SSTIs are associated with a broad range of
potential pathogens (Table 1) (Doern et al 1999; Jones et al
1999, 2003; Bowler et al 2001; Fung et al 2003; Rennie et
al 2003; Jodrá et al 2006). Aerobic Gram-positive cocci are
the predominant pathogens in most types of cSSTIs,
particularly those that are community-acquired in origin.
Staphylococcus aureus, other staphylococci, and various
Table 1 Bacterial pathogens associated with complicated skin
and soft tissue infections (Doern et al 1999; Jones et al 1999,
2003; Bowler et al 2001; Fung et al 2003; Rennie et al 2003;
Jodrá et al 2006)
Frequency of isolation
Organism All Hospital-
 infections acquired
(%)
a infections (%)
Gram-positive aerobes 57–60 29–55
Staphylococcus aureus (all) 29–46 13–19
Staphylococcus aureus (MR) 3–15 8–12
Coagulase-negative staphylococci 3–5 6–13
Streptococci 7–20 3–4
Enterococcus spp. 3–8 5–14
Gram-negative aerobes 22–26 25–47
Pseudomonas aeruginosa 3–11 3–9
Escherichia coli 4–13 7–12
Enterobacter spp. 5–6 4–9
Klebsiella pneumoniae 3–4 4–6
Proteus spp. 4–6 2–4
Acinetobacter spp. ND 3–4
Serratia spp. 2–3 1–4
Anaerobes 17–33 ND
Bacteroides spp. 5–13 ND
Peptostreptococcus spp. 4–8 ND
Prevotella spp. 3 ND
Clostridium spp. 1 ND
Note: 
aInfections in patients requiring hospitalization for treatment.
Abbreviations: MR, methicillin-resistant; ND, no data reported.Therapeutics and Clinical Risk Management 2006:2(4) 403
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streptococci (particularly of groups A and B) are the most
common organisms (Bowler et al 2001; Fung et al 2003;
Raghavan and Linden 2004). The incidence of infections
caused by methicillin-resistant S. aureus (MRSA) has been
steadily increasing; MRSA now accounts for approximately
60% of all S. aureus isolates from nosocomial infections in
the US (DPH 2004). Even more alarming is the growing
incidence of infections due to community-acquired MRSA.
Although MRSA has been traditionally regarded as a
hospital-acquired pathogen, this organism has also emerged
as a common cause of community-acquired infections with
approximately 30% of all MRSA isolates now community-
acquired in origin (Burkharie et al 2001; Eady and Cove
2003). A recent study of MRSA infections in three
geographic areas within the US reported that 17% of all
isolates were community-acquired in origin (Fridkin et al
2005). This study also found that 77% of these infections
involved skin and soft tissue, and the overall incidence of
community-acquired MRSA infections was significantly
higher among persons less than two years of age.
Specifically in cSSTIs, MRSA has been reported in up to
10%–15% of patients overall, and 5%–15% of patients with
nosocomial infections (Jones et al 1999, 2003; Fung et al
2003; Rennie et al 2003; DPH 2004; Raghavan and Linden
2004). Enterococci are also common pathogens in cSSTIs
and are isolated with somewhat greater frequency in
nosocomial infections (Jones et al 1999, 2003; Bowler et al
2001; Raghavan and Linden 2004). Up to 20% of
enterococci isolated from these infections are now
vancomycin-resistant (VRE) (Rennie et al 2003; Raghavan
and Linden 2004). S. aureus, enterococci, and coagulase-
negative staphylococci are particularly important pathogens
in surgical wound infections and together account for
approximately 46% of all surgical site infections; both
MRSA and VRE occur more frequently in these infections
as well (DiNubile and Lipsky 2004; DPH 2004).
Gram-negative organisms which are frequently seen in
cSSTIs include the Enterobacteriaceae (particularly
Escherichia coli, Enterobacter spp., Klebsiella spp., and
Proteus spp.) and P. aeruginosa (Jones et al 1999, 2003;
Swartz 2000; Fung et al 2003; Rennie et al 2003; Stevens et
al 2005). Complicated skin and soft tissue infections
commonly associated with P. aeruginosa include lower
extremity infections (particularly in patients with
comorbidities such as vascular insufficiency or diabetes),
surgical wound infections, chronic renal disease, and
diabetes or other immunocompromising diseases (Bowler
et al 2001; Pellizer et al 2001; Eron et al 2003; Rennie et al
2003; DPH 2004; Lipsky et al 2004). Of particular concern
is the rapid spread of resistance mediated by extended-
spectrum β-lactamases (ESBLs) among organisms such as
Klebsiella pneumoniae and Escherichia coli. Organisms that
produce ESBLs are usually resistant to multiple
antimicrobials including third-generation (eg, ceftriaxone,
cefotaxime, ceftazidime) and fourth-generation (ie,
cefepime) cephalosporins and aztreonam (Bush 2001;
Paterson et al 2003), and are also associated with high rates
of resistance to aminoglycosides and fluoroquinolones
(Paterson et al 2000, 2003). Although recent data for cSSTIs
are not readily available, a recent international study of
Gram-negative bacilli isolated from intra-abdominal
infections found 7% of E. coli, 13% of Klebsiella spp., and
18% of Enterobacter spp. were ESBL producers (Chow et
al 2006). These data are consistent with data reported
specifically from the US, although rates may be higher in
certain geographical areas (DPH 2004; Pfaller and Segreti
2006). Resistance of P. aeruginosa to fluoroquinolones,
ceftazidime, and imipenem/cilastatin has also increased
rapidly; nearly 10% of P. aeruginosa isolates are now
resistant to multiple drug classes including cephalosporins,
carbapenems, aminoglycosides, and/or fluoroquinolones
(Karlowsky et al 2003). Reports of fluoroquinolone
resistance are becoming more common among organisms
such as E. coli and Proteus spp. that are usually considered
to be very susceptible to this class of drugs (Neuhauser et al
2003; Zervos et al 2003).
Anaerobic bacteria such as Bacteroides fragilis, other
bacteria of the Bacteroides group, Fusobacterium spp.,
Prevotella spp., Clostridium spp., and Peptostreptococcus
spp. are also relatively common causes of certain cSSTIs.
Types of infections in which anaerobes are commonly found
include traumatic wounds, infections in diabetic and other
immunocompromised patients, and infections associated
with ischemic tissue injury (Jones et al 2003). Increasing
resistance to common antibiotics such as clindamycin and
second-generation cephalosporins (eg, cefoxitin, cefotetan)
has been documented among anaerobic bacteria such as B.
fragilis and organisms of the Bacteroides group (Hecht
2004). However, agents such as metronidazole, piperacillin/
tazobactam, and the carbapenems still maintain excellent
activity against most clinically relevant anaerobic bacteria.
This broad range of potential pathogens is further
complicated by the fact that many cSSTIs are polymicrobial
and represent a variety of mixed infections, ie, presence of
aerobic Gram-positive and Gram-negative pathogens as well
as anaerobes (Nichols 1999; Fung et al 2003; Stevens et alTherapeutics and Clinical Risk Management 2006:2(4) 404
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2005). Classic mixed aerobic and anaerobic infections are
particularly common in surgical wound infections,
necrotizing infections including fasciitis and myositis,
complex and perirectal abscesses, diabetic and ischemic
ulcers, and complicated cellulitis in diabetics and other
immunocompromised patients (Nichols 1999; Pellizer et al
2001; Fung et al 2003; Lipsky et al 2004; Stevens et al 2005;
Vinh and Embil 2005).
The recent emergence and spread of antibiotic resistance
among both Gram-positive and Gram-negative pathogens
have created a significant clinical challenge in the
appropriate management of cSSTIs (Colsky et al 1998;
Sader et al 2002; Rennie et al 2003). Although a number of
drugs for treatment of multidrug-resistant organisms such
as MRSA and VRE have become available or are in
development (eg, linezolid, daptomycin, tigecycline,
dalbavancin), there are few drugs under development for
treatment of Gram-negative or anaerobic pathogens which
are resistant to the currently available agents. Thus there is
a clear need for new antibiotic options for treatment of cSSTI
as a result of increasing bacterial resistance. What is equally
clear is that the use of currently available agents also needs
to be optimized to increase or improve the effective
therapeutic options.
Considerations in antibiotic selection
Appropriate therapeutic strategies for cSSTIs depend on a
number of factors including whether the infection is
community- versus hospital-acquired in origin, virulence
of the infecting pathogens, severity, and presence and type
of comorbidities. Surgical intervention will often be required
and antibiotic therapy is often considered an adjunctive
rather than a primary therapy for certain infections, eg,
diabetic foot infections or necrotizing fasciitis (Eron et al
2003; Lipsky et al 2004; Stevens et al 2005). However,
adequate antibiotic therapy remains a crucial component of
appropriate management of cSSTIs. Empirical antibiotic
therapy should usually be promptly initiated after obtaining
samples for culture in order to begin appropriate treatment
and slow the progression of the infection (Nichols 1999;
Eron et al 2003; Stevens et al 2005).
Selection of a specific antibiotic regimen for treatment
of cSSTIs depends on many factors such as etiology of the
infection (ie, community- or hospital-acquired), knowledge
of local or institutional antibiotic susceptibility patterns,
availability of suitable antibiotics which provide appropriate
spectrum of activity for known or presumed pathogens,
pharmacokinetic and pharmacodynamic considerations such
as penetration of infected tissues and ability to achieve
suitable drug concentrations, adverse effect and drug
interaction profiles, and drug cost (Nichols 1999; Eron et al
2003; Fung et al 2003; DiNubile and Lipsky 2004). Because
of the broad range of pathogens associated with cSSTIs and
the frequency of mixed infections involving both aerobic
and anaerobic bacteria, empirical antibiotic regimens are
usually broad in spectrum and provide coverage against both
Gram-positive and Gram-negative pathogens, with the
addition of anaerobic activity also often desired (Nichols
1999; Eron et al 2003; Fung et al 2003; Lipsky et al 2004;
Stevens et al 2005). Although streamlining of antibiotic
therapy to narrower-spectrum regimens is appropriate once
results of microbiological cultures are known, initial
antibiotics must be sufficiently broad to cover potential
pathogens until other management modalities (ie, surgical
intervention) can be instituted.
It has been well documented that increasing resistance
among bacterial pathogens results in inappropriate selection
of antibiotic therapy for hospital-acquired pneumonia and
bloodstream infections (Rello et al 1993; Alvarez-Lerma et
al 1996; Luna et al 1997; Leibovici et al 1998; Carmeli et al
1999; Kollef et al 1999; Garnacho-Montero et al 2003).
Furthermore, the relationship between inappropriate
antibiotic selection and resultant mortality in pneumonia
and sepsis has been clearly shown (Rello et al 1993; Alvarez-
Lerma et al 1996; Luna et al 1997; Leibovici et al 1998;
Carmeli et al 1999; Kollef et al 1999). Similar data
specifically addressing the association between
inappropriate antibiotic selection and subsequent adverse
outcomes are not as plentiful for cSSTIs. However, one
retrospective study of 137 patients with intra-abdominal
infections and SSTIs treated with cefotetan, cefoxitin, or
ampicillin/sulbactam monotherapy found that isolation of a
pathogen resistant to the antibiotic treatment regimen
(particularly P. aeruginosa) was an independent risk factor
for clinical treatment failure with multivariate analysis (odds
ratio [OR] = 14.9; p=0.001) (Falagas et al 1996). Improper
antibiotic selection thus has adverse consequences in cSSTIs
as well. Because the bacterial etiology of cSSTIs often
involves polymicrobial infections and because of the
changing patterns of antibiotic susceptibilities among both
Gram-positive and Gram-negative pathogens, the empirical
use of antibiotics with a broad spectrum of activity which
includes multidrug-resistant organisms is becoming
increasingly common and ever more appropriate (Nichols
1999; Eron et al 2003; Fung et al 2003; Lipsky et al 2004;
Stevens et al 2005).Therapeutics and Clinical Risk Management 2006:2(4) 405
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Meropenem in the treatment of
cSSTIs
Antibacterial spectrum of activity
Meropenem is a broad-spectrum carbapenem antibiotic that
possesses excellent activity against both aerobic Gram-
positive and aerobic Gram-negative bacteria, and also covers
common anaerobes. Based on published MIC90s (the
minimum inhibitory concentration at which 90% of tested
strains are inhibited), meropenem is generally similar to or
slightly less active than imipenem/cilastatin or ertapenem
against Gram-positive aerobic bacteria. However, these
differences are not likely to be clinically significant for most
pathogens because MIC90s are usually well below
recommended susceptibility breakpoints (Wiseman et al
1995; Fish and Singletary 1997; Merrem
® product package
insert 2005). Meropenem is active against methicillin-
susceptible S. aureus and most strains of methicillin-
susceptible coagulase-negative staphylococci. However, as
with other carbapenems, meropenem has poor activity
against MRSA and methicillin-resistant coagulase-negative
staphylococci. Meropenem also has excellent activity
against most streptococci, including Streptococcus pyogenes
and S. agalactiae. The activity of meropenem against
enterococci varies considerably among different species.
Most strains of Enterococcus faecalis, E. avium and E.
liquefaciens are susceptible or moderately susceptible to
meropenem, but most strains of E. faecium and VRE of any
species are resistant.
Meropenem has impressive in vitro activity against
Gram-negative aerobic bacteria and compares very
favorably against both imipenem/cilastatin and ertapenem.
Meropenem is generally slightly more active than imipenem/
cilastatin (based on MIC90s) and similar in activity to
ertapenem against clinical isolates of Enterobacteriaceae.
Meropenem has shown excellent efficacy against clinical
isolates resistant to other β-lactam agents, including many
strains which were highly resistant to third-generation
cephalosporins, piperacillin, and aminoglycosides.
Meropenem and other carbapenems are considered to be
drugs of choice for the treatment of the ESBL-producing
Gram-negative bacilli (Paterson et al 2000, 2003). Although
meropenem generally has 1- to 2-fold lower MIC90s than
imipenem/cilastatin against P. aeruginosa, these two drugs
appear to be relatively similar in their in vitro activity against
clinical isolates of this organism. However, meropenem and
imipenem/cilastatin are affected by somewhat different
mechanisms of resistance among P. aeruginosa strains and
cross-resistance among the two drugs is not complete (Fish
and Singletary 1997; Rhomberg et al 2005; Quale et al 2006).
The Meropenem Yearly Susceptibility Test Information
Collection (MYSTIC) surveillance database of antibiotic
susceptibilities reports that approximately 7% of P.
aeruginosa strains are resistant to imipenem/cilastatin but
susceptible to meropenem, while only approximately 1%
of strains were susceptible to imipenem/cilastatin and
resistant to meropenem (AstraZeneca 2006). Such
discordant susceptibilities are consistent with data published
elsewhere (Wiseman et al 1995; Fish and Singletary 1997;
Mutnick et al 2004), although the drugs are considered to
be equivalent in P. aeruginosa activity under most clinical
circumstances. Ertapenem is not reliably active against P.
aeruginosa and is not generally considered to be clinically
useful for infections caused by this organism (Fuchs et al
2001; Livermore et al 2001).
Meropenem is also active against most strains of
clinically significant anaerobes. Meropenem displayed
MIC90s which were quite similar to those for imipenem/
cilastatin and ertapenem in Gram-negative isolates including
Bacteroides fragilis, Bacteroides group, and Fusobacterium
spp. Meropenem MICs for these organisms are usually
substantially lower than those of metronidazole,
clindamycin, cefoxitin, or piperacillin/tazobactam. Against
Gram-positive anaerobic bacteria such as Clostridium
perfringens, C. difficile and Veillonella spp., meropenem is
equal to or slightly more active than imipenem/cilastatin,
ertapenem, metronidazole, clindamycin, cefoxitin or
piperacillin/tazobactam. Meropenem also has excellent
activity against clinical isolates of Peptostreptococcus spp.,
Propionibacterium acnes,  Actinomyces spp., and
Actinobacillus spp. (Wiseman et al 1995; Fish and Singletary
1997).
Considerations regarding
pharmacokinetics/pharmacodynamics
and tissue penetration
Meropenem achieves mean peak plasma concentrations
(Cmax) and minimum plasma concentrations (Cmin) of
approximately 23–25 mg/L and 0.1–0.2 mg/L, respectively,
following the administration of single or multiple 30-minute
intravenous infusions of 500 mg to healthy adult volunteers
(Maglio et al 2003; Merrem
® product package insert 2005).
Although Cmin values for meropenem are relatively low, the
drug is extremely active against many pathogens commonly
found in cSSTIs with MIC90s of ≤0.12 mg/L for mostTherapeutics and Clinical Risk Management 2006:2(4) 406
Fish
Enterobacteriaceae, methicillin-susceptible S. aureus and
coagulase-negative staphylococci, and streptococci
(Rhomberg et al 2005). Studies of carbapenems indicate
that the percentage of the dosing interval during which
concentrations of free (ie, not protein bound) drug remain
above the MIC of the pathogen (referred to as the percent
time above MIC, or % T>MIC) is the key pharmacodynamic
parameter which is related to clinical and microbiological
efficacy of the drugs. A ≥30% T>MIC is associated with
bacteriostatic activity of the carbapenems, while a ≥40%
T>MIC is more predictably bactericidal and associated with
prevention of the development of resistance (Craig 1998;
Turnidge 1998). Meropenem 500 mg every 8 hours achieves
T>MIC of ≥40% for most susceptible pathogens and would
be expected to be effective in the treatment of cSSTIs caused
by these organisms at this dose.
Meropenem appears to be widely distributed in various
body tissues and fluids (Hutchison et al 1995; Mouton et al
1995; Fish and Singletary 1997). Specifically regarding the
use of meropenem in the treatment of cSSTIs, several early
studies demonstrated that meropenem achieves
concentrations adequate for the treatment of infections
caused by susceptible bacteria in skin, burned skin, fascia,
skeletal muscle, and blister fluid (Table 2). Meropenem
concentrations in these various tissues were quite variable
and ranged from 9% to 85% of simultaneous serum
concentrations; however, the absolute concentrations were
nevertheless in excess of the susceptibility breakpoints (MIC
≤4 mg/L) of bacteria commonly found in cSSTIs (Hutchison
et al 1995; Mouton et al 1995; Fish and Singletary 1997). A
more recent study also evaluated the pharmacokinetic
disposition of meropenem in plasma and cantharidin-
induced blister fluid (Maglio et al 2003). The mean
penetration of meropenem into blister fluid was determined
to be 67% when calculated by comparing the
pharmacokinetic area under the concentration-time curve
(AUC) of the drug in blister fluid with the AUC of
meropenem in plasma. Additionally, this study found that
meropenem doses of 500 mg every 8 hours maintains a
≥50% T>MIC in blister fluid for most susceptible pathogens.
This study thus indicated that meropenem 500 mg every 8
hours achieves concentrations in blister fluid sufficient for
the treatment of SSTIs caused by susceptible organisms
(Maglio et al 2003).
Another recent study used data concerning
pharmacokinetics and penetration into blister fluid in order
to model the phamacodynamics of meropenem, imipenem/
cilastatin and piperacillin/tazobactam in the treatment of
cSSTIs (Ong et al 2005). This study utilized Monte Carlo
simulation, a statistical modeling tool which combines both
pharmacokinetic and MIC information to predict the
probability of achieving desired pharmacodynamic targets
with various drug dosing regimens and against specific
pathogens. Optimal pharmacodynamic targets with common
dosing regimens of each specific agent were defined as
≥90% probability of ≥40% T>MIC (meropenem and
imipenem/cilastain) or ≥50% T>MIC (piperacillin/
tazobactam) in serum and blister fluid. Meropenem 500 mg
every 8 hours, imipenem/cilastain 500 mg every 8 hours,
and piperacillin/tazobactam 3.375 g every 6 hours were all
determined to be optimal choices for empiric treatment of
cSSTIs. This study offers further support for the suitability
of meropenem as an appropriate agent for the treatment of
these infections (Ong et al 2005).
The further application of Monte Carlo simulation to
meropenem pharmacodynamics raises important questions
related to the optimal dosing of this agent for cSSTIs.
Although the previously cited studies provide
pharmacokinetic and pharmacodynamic data indicating that
meropenem 500 mg every 8 hours is an adequate regimen
for infections involving most susceptible pathogens, the
adequacy of this regimen specifically for infections
Table 2 Concentration of meropenem in tissues involved in complicated skin and soft tissue infections
Dose Sample Mean drug concentration (mg/L) Tissue/fluid:serum
Body tissue or fluid N (g) time (hrs) Tissue/fluid Serum Ratio
Skeletal muscle 14 1 0.5–4.5 0.93–6.10 - -
Fascia 18 1 0.5–5.5 0.99–8.76 - -
Skin 3 0.5 0 3.97 42.6 9.6%
0.5 1 3.4 11.9 33.5%
Burned skin 2 1 0 5.5 64.3 8.8%
1 1 9.2 14.8 61.6%
Blister fluid 8 10 mg/kg 3.5–4.5 1.36 1.44 85%
Blister fluid 6 1 3.5–4.5 4.94 2.07 >38%Therapeutics and Clinical Risk Management 2006:2(4) 407
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involving P. aeruginosa is less clear. Other published Monte
Carlo evaluations of meropenem pharmacodynamics
indicate that even regimens of 1 g every 8 hours often fail
to produce desired (≥90% probability), and sometimes not
even acceptable (≥80% probability) likelihood of attaining
the desired pharmacodynamic target of ≥40% T>MIC for
P. aeruginosa (Kuti et al 2004; Masterton et al 2005). While
the probabilities of achieving specified pharmacodynamic
targets for P. aeruginosa isolates from different geographic
regions ranged from 63% to 91% with meropenem 1 g every
8 hours, probabilities of target attainment with the regimen
of 500mg every 8 hours ranged from only 59% to 81% (Kuti
et al 2004; Masterton et al 2005). These analyses were
performed utilizing MIC data from the MYSTIC database,
but P. aeruginosa susceptibilities of isolates obtained from
different geographic regions, specific institutions, and even
individual patients may be very different from those in
MYSTIC and would therefore yield quite different
probabilities of pharmacodynamic target attainment (either
higher or lower). Although a previous analysis of
meropenem for cSSTIs indicated a high probability of
achieving desired pharmacodynamic goals with the regimen
of 500 mg every 8 hours, this analysis was based on pooled
susceptibility data in which MIC data were weighted
according to the prevalence of causative pathogens
encountered in cSSTIs and did not report probability of
target attainment specifically for P. aeruginosa (Ong et al
2005) Based on pharmacodynamic considerations, it appears
that meropenem 500 mg every 8 hours is not necessarily
optimal for the treatment of cSSTIs or other infections when
P. aeruginosa is suspected or documented. Meropenem 1 g
every 8 hours may be a more preferred regimen in these
cases.
The elimination half-life of meropenem is approximately
one hour in patients with normal renal function. The major
route of meropenem elimination is urinary excretion of
unchanged drug, with renal clearance (CLR) accounting for
58%–83% of total systemic clearance of the drug and up to
98% of each dose eventually excreted in the urine as
unchanged meropenem and as a pharmacologically inactive,
open β-lactam metabolite (Wiseman et al 1995; Fish and
Singletary 1997). It appears that meropenem
pharmacokinetics in children ≥6 months of age are very
similar to those seen in adults.
Because many cSSTIs occur in the setting of diabetes
mellitus and other acute or chronic illnesses associated with
renal dysfunction, the disposition of meropenem in patients
with renal impairment is of relevance. Following
intravenous administration, meropenem AUC, CLR, and total
systemic clearance are altered in proportion to the degree
of renal impairment present. Dosage adjustments are
therefore required in patients with moderate to severe renal
insufficiency and calculated creatinine clearances of <50mL/
minute in order to prevent excessive drug accumulation.
Dosage adjustments of meropenem in elderly patients are
also  based  on  renal  function  with  no  other  apparent
age-related pharmacokinetic alterations. The
pharmacokinetics of meropenem are not significantly
altered in patients with hepatic impairment and no dosage
adjustments are required (Wiseman et al 1995; Fish and
Singletary 1997).
Clinical data
At least three studies have evaluated meropenem in the
treatment of cSSTIs (Table 3) (Lami et al 1991; Nichols et
al 1995; Fabian et al 2005). The first of these was a small
prospective, open-label study comparing meropenem with
imipenem/cilastatin in patients with soft tissue infections
requiring hospitalization, surgical drainage, and/or
debridement in addition to antibiotic therapy (Lami et al
1991). Pertinent among the exclusion criteria were patients
with neutropenia or diabetic foot infections requiring
amputation; clinically evaluable patients were required to
have documented bacterial pathogens. Patients were
randomized to receive either meropenem 500 mg every 8
hours (23 evaluable patients) or imipenem/cilastatin 500 mg
every 6 hours (21 patients); patients in both groups were
treated for a mean duration of approximately 7 days. Patients
in the two treatment groups were similar with regards to
demographics, severity and type of infections. S. aureus,
streptococci, and E. coli were the most common pathogens
with a mean of three bacterial isolates per patient.
Satisfactory clinical responses were demonstrated in 100%
of patients in both treatment groups; microbiological
response rates and the number of infections caused
specifically by P. aeruginosa were not reported. Both
antibiotic regimens were well tolerated with an apparently
low reported incidence of adverse events.
A second study also evaluated the efficacy of meropenem
compared with imipenem/cilastatin in the treatment of severe
infections (Nichols et al 1995). This was a prospective,
randomized, multicenter, open-label study. The primary
inclusion criteria were requirement for hospitalization and
treatment with parenteral antibiotics; the specific types of
infections eligible for inclusion in the study were not well
defined. Relevant exclusion criteria included neutropenia,Therapeutics and Clinical Risk Management 2006:2(4) 408
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rapidly progressive disease, and severe peripheral vascular
disease likely to require amputation. Patients received either
meropenem 500 mg every 8 hours (123 evaluable patients)
or imipenem/cilastatin 500 mg every 6 hours (126 patients);
patients in both groups were treated for a mean duration of
approximately 6 days. Primary study endpoints were clinical
and bacteriologic responses at the end of therapy and at a
follow-up visit 2 to 4 weeks after the end of therapy.
Treatment groups were similar with respect to patient
demographics, diagnoses, or required surgical procedures
during treatment. Greater than 97% of infections were
community-acquired and included patients with diabetes,
peripheral vascular disease, and injection drug use-related
infections. Approximately half of all infections were
monomicrobial and involved a Gram-positive organism in
86% of these patients. Polymicrobic infections were
documented in 48% of meropenem-treated patients and 45%
of patients receiving imipenem/cilastatin. The overall
distribution of pathogens in these patients was 58% aerobic
Gram-positive bacteria, 22% aerobic Gram-negatives, and
20% anaerobes. Satisfactory clinical responses at end of
treatment were similar between the groups treated with
meropenem and imipenem/cilastatin (98% versus 95%,
respectively; 95% confidence interval [CI], −2.29 to 6.93).
Microbiological response rates at end of treatment in the
meropenem and imipenem/cilastatin groups were also
similar (94% and 91%, respectively; 95% CI, −2.73 to
10.39); however, meropenem was statistically better than
imipenem/cilastatin in overall eradication of pathogens (96%
vs 90%, respectively; p=0.007) and eradication of gram-
positive aerobes (96% vs 88%, respectively; p=0.01).
Although P. aeruginosa was reported to be eradicated in 9
of 11 patients (82%), this rate was somewhat lower than
that reported for other Gram-negative pathogens (48 of 50,
96%). Clinical efficacy rates in meropenem and imipenem/
cilastatin groups at the 2- to 4-week follow-up visit were
92% and 89%, respectively (p=0.60), while microbiological
efficacy at follow-up was 92% versus 82%, respectively
(p=0.11). Superinfection due to S. aureus was
documented in one meropenem-treated patient; the
incidence of other drug-related adverse events was similar
between groups.
Although these first two studies provide support for
meropenem’s efficacy in the treatment of cSSTIs, they had
potential limitations in assessing the role of meropenem
specifically for complicated infections. First, it is not clear
whether these studies actually evaluated the treatment of
complicated infections as these are currently defined. Both
studies included patients with infections requiring
hospitalization and surgical intervention, so these infections
do appear to have been more severe or complicated in nature,
or both. However, the sites and types of infections eligible
for inclusion in the studies were not always well defined.
The 100% efficacy rates reported in the first study are also
somewhat suspect for complicated infections (Lami et al
1991); this may reflect the unblinded nature of the study
rather than the possibility that the infections were not truly
complicated in nature. In the second study (Nichols et al
1995), the infections were overwhelmingly community-
acquired in origin. Although these were appropriate for
evaluation, the study did not represent the full spectrum of
infections (eg, surgical wound infections, other nosocomial
infections) of importance in cSSTIs. Thus although the
overall results of these two studies were favorable for
meropenem, they both had relative limitations regarding
study design and/or enrolled patient populations which make
Table 3 Summary of meropenem clinical efficacy trials in complicated skin and soft tissue infections
Response
Mean
Evaluable duration of Clinical Bacteriologic Drug-
Reference Study type patients Regimen therapy (%) (%) related
(N) (days) AE (%)
Lami et al 1991 P, R, NB 23 M 500 mg q8h 6.4 100 NR NR
21 I/C 500 mg q6h 6.5 100 NR NR
Nichols et al 1995 P, R, MC, NB 123 M 500 mg q8h 7.1 98 94 14
126 I/C 500 mg q6h 7.3 95 91 16
Fabian et al 2005 P, R, MC, DB 261 M 500 mg q8h 5.8 
a 86.2 88.5 9.0
287 I/C 500 mg q8h 6.0 a 82.9 83.1 10.8
Note: 
aNumbers in table represent duration of parenteral therapy only. Approximately 50% of patients in each treatment group were switched to oral therapy and
treated for an additional mean of 9.3 and 9.0 days in meropenem and I/C groups, respectively.
Abbreviations: AE, adverse events; DB, double-blind; I/C, imipenem/cilastatin; M, meropenem; MC, multicentered; NB, non-blinded; NR, not reported; P, prospective;
R, randomized.Therapeutics and Clinical Risk Management 2006:2(4) 409
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the significance and applicability of the results difficult to
fully evaluate.
The best and most recent study of meropenem in the
treatment of cSSTIs overcame the deficiencies of the two
earlier, previously-described studies. This large prospective,
randomized, multicenter, international, double-blind study
compared the efficacy and safety of meropenem 500 mg
every 8 hours versus imipenem/cilastatin 500 mg every 8
hours in hospitalized patients with cSSTIs (Fabian et al
2005). Infections classified as complicated for purposes of
this study included the following: complicated cellulitis (ie,
in the setting of diabetes, involving the perineum, or deep
tissue involvement evidenced by necrosis, tissue fluctuance,
bacteremia, or need for surgical incision); surgical site
infections; traumatic infections; infected diabetic and
ischemic ulcers; complex or perirectal abscesses, or other
bacterial infections requiring hospitalization, surgical
intervention, and parenteral antibiotics. In addition, all
patients were required to have had specimens for culture
and susceptibility testing obtained before study enrollment;
any pathogens known to be present at study enrollment were
required to be susceptible to study drugs. Pertinent exclusion
criteria included neutropenia, underlying osteomyelitis,
severe peripheral vascular disease likely to require
amputation, necrotizing fasciitis, pressure ulcerations, or
infected prosthetic materials. Concomitant therapy with
vancomycin or other systemic antibiotics was not permitted;
patients could be switched to oral antibiotics of the
investigators’ choice after a minimum of three days of
parenteral therapy. The primary study endpoints were
clinical efficacy (cure versus failure or relapse) in clinically
evaluable (CE) and modified intent-to-treat (MITT, patients
meeting all eligibility criteria and receiving ≥1 dose of drug)
populations at a follow-up test-of-cure (TOC) visit 7 to 28
days after completion of all antibiotics. Secondary endpoints
included clinical efficacy in the intent-to-treat (ITT, all
patients receiving ≥1 dose of drug whether or not they met
eligibility criteria) population at the TOC follow-up visit,
as well as clinical efficacy in the ITT, MITT, and CE
populations at the end-of-therapy visit occurring within 24
hours of completion of antibiotic therapy.
A total of 1076 patients were enrolled into the study. Of
these, final study populations treated with meropenem and
imipenem/cilastatin included 510 and 527 patients,
respectively, in the ITT groups; 334 and 358 patients,
respectively, in the MITT groups; and 261 and 287 patients,
respectively, in the CE groups. Treatment groups were
similar in respect to patient demographics, types of infection,
and underlying medical conditions. Approximately 93% of
patients in each group had infections classified as moderate
or severe in nature, and 80% in each treatment arm had
deep tissue involvement. Additionally, 68% of patients
treated with meropenem and 70% of those receiving
imipenem/cilastatin required surgical intervention. In
contrast to the two earlier studies, approximately 18% of
patients in both groups had surgical site or traumatic wound
infections. Isolated pathogens were also evenly represented
among the two treatment groups. Aerobic Gram-positive
organisms accounted for 57% of pre-treatment pathogens,
while aerobic Gram-negative pathogens were found in 26%
of patients and anaerobes in 17% (Table 4). Polymicrobial
infections were microbiologically documented in 38% of
patients at pre-treatment baseline.
The mean duration of therapy with intravenous therapy
was approximately 6 days in both groups, similar numbers
of patients in each group were switched to oral antibiotics
(approximately 50%), and the mean duration of oral
antibiotics was also similar between groups (approximately
9 days). Evaluation of the primary study endpoints
demonstrated equivalent efficacy between meropenem and
imipenem/cilastatin within both the CE (86.2% vs 82.9%,
respectively; 95% CI, −2.8 to 9.3) and MITT populations
(73.1% vs 74.9%, respectively; 95% CI, −8.4 to 4.7). There
were also no statistically significant differences between
meropenem and imipenem/cilastatin among the secondary
endpoints. Clinical efficacy rates in the meropenem and
imipenem/cilastatin groups within the ITT population at the
Table 4 Pre-treatment pathogens isolated from patients with
complicated skin and soft tissue infections (Fabian et al 2005)
Total pathogens 1444 (100%)
Gram-positive aerobes 827 (57%)
Staphylococcus aureus (MS) 295 (20%)
Staphylococcus aureus (MR) 118 (8%)
Streptococcus pyogenes 89 (6%)
Streptococcus agalactiae 59 (4%)
Enterococcus faecalis 52 (4%)
Gram-negative aerobes 378 (26%)
Escherichia coli 64 (4%)
Pseudomonas aeruginosa 53 (4%)
Proteus spp. 52 (4%)
Klebsiella spp. 41 (3%)
Anaerobes 239 (17%)
Bacteroides fragilis 74 (5%)
Peptostreptococcus spp. 63 (4%)
Prevotella spp. 46 (3%)
Monomicrobial infections 895 (62%)
Polymicrobial infections 549 (38%)
Abbreviations: MS, methicillin-susceptible; MR, methicillin-resistant.Therapeutics and Clinical Risk Management 2006:2(4) 410
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TOC visit (approximately 57% vs 61%, respectively; 95%
CI, −9.8 to 2.1), and within the CE (93.5% vs 92.3%,
respectively; approximate 95% CI, −3.1 to 5.4), MITT
(91.0% vs 91.1%, respectively; approximate 95% CI, −4.3
to 4.2), and ITT (81.0% vs 83.5%, respectively; approximate
95% CI, −7.1 to 2.0) populations at the end-of-treatment
evaluations were all similar among the two treatment groups.
Again, no significant differences in efficacy among the
meropenem and imipenem/cilastatin groups were observed
when patients were divided into subgroups according to
demographic parameters, types of infection, or infecting
pathogens. Clinical cure rates specifically in patients
infected with P. aeruginosa and treated with meropenem
and imipenem/cilastatin were 73.3% (11/15) and 86.7% (13/
15), respectively (p=0.652). The incidence of drug-related
adverse events was similar between meropenem and
imipenem/cilastatin groups (9.0% vs 10.8%, respectively).
Additional data from this study regarding the
bacteriology and clinical efficacy of meropenem and
imipenem/cilastatin specifically in diabetic patients were
recently presented at an international meeting (Embil et al
2005). A total of 398 patients (38%) enrolled into the study
had diabetes mellitus. Of these patients, 254 (82%) had
infections involving the leg or foot, or both, most commonly
complicated cellulitis, complex abscess, or infected ulcers.
The distribution of pathogens in these patients was 58%
aerobic Gram-positive bacteria, 27% aerobic Gram-
negatives, and 15% anaerobes. This distribution of
pathogens was similar to that seen in non-diabetic patients,
although the frequency of polymicrobial infection was
greater in diabetic versus non-diabetic patients (44% versus
34%, respectively; p=0.002). Clinical efficacy rates among
all enrolled patients at follow-up were significantly higher
with meropenem vs. imipenem/cilastatin in diabetic patients
(86% vs 72%, respectively; p<0.0001) but not in non-
diabetic patients (87% vs 89%, respectively; p=0.322).
Clinical efficacy rates among microbiologically evaluable
diabetic patients were also significantly higher for infections
caused by various bacteria among meropenem-treated
patients compared with those receiving imipenem/cilastatin
(Gram-positive aerobes, 87% vs 70%; Gram-negative
aerobes, 74% vs 60%; anaerobes, 94% vs 71%; and
polymicrobial infections, 88% vs 65%, respectively;
p<0.0001 for each of the four comparisons). Possible reasons
for these reported differences in efficacy are not clear.
Although previous studies used imipenem/cilastatin doses
of 500 mg every 6 hours (Lami et al 1991; Nichols et al
1995), the lower dose of 500 mg every 8 hours used in this
third study has been shown to be apparently adequate for
the treatment of cSSTIs based on pharmacodynamic
modeling (Ong et al 2005). In addition, since this abstract
reported data from an unplanned subgroup analysis of the
original study, the post-hoc statistical comparisons do not
necessarily indicate that meropenem is superior to
imipenem/cilastatin in the treatment of cSSTIs in diabetic
patients. However, the data do indicate that meropenem is
at least comparable with imipenem/cilastatin and is quite
an effective agent in the treatment of such infections.
Based on available data as reviewed in this article,
meropenem was approved by the FDA on May 25, 2005 for
the treatment of cSSTIs at a dose of 500 mg intravenously
every 8 hours. Meropenem is specifically indicated for
cSSTIs caused by the following pathogens: S. aureus
(methicillin susceptible only), S. pyogenes, S. agalactiae,
viridans group streptococci, E. faecalis (vancomycin
susceptible only), E. coli, P. mirabilis, P. aeruginosa, B.
fragilis, or Peptostreptococcus spp.
Role of meropenem in cSSTIs
Complicated skin and soft tissue infections continue to
represent a considerable clinical challenge. The underlying
conditions such as diabetes mellitus, peripheral vascular
disease, surgery, and immunosuppression that predispose
to cSSTIs also make them potentially less responsive to
traditional antibiotic therapy, thus necessitating hospital
admission for parenteral antibiotics and surgical
interventions. The broad range of bacterial pathogens likely
to be encountered in cSSTIs, together with the changing
epidemiology of susceptibilities to currently available
antibiotics, adds to the complexity of managing these
infections. As previously discussed, meropenem has
excellent activity against most bacteria commonly associated
with cSSTIs, often including P. aeruginosa and ESBL-
producing organisms which are resistant to other β-lactam
antibiotics including third-generation cephalosporins. The
status of carbapenems as the drugs of choice in the treatment
of infection due to ESBL-producing organisms makes
meropenem and other agents of this class particularly
attractive in geographic areas with high prevalence of ESBL
producers. Meropenem’s broad antimicrobial spectrum of
action is thus well suited to either empiric treatment of
cSSTIs when specific pathogens are unknown, as well as
definitive treatment of mixed bacterial infections and/or
those caused by multidrug-resistant organisms once specific
pathogens and susceptibilities have been documented.
However, because of the recent emergence of community-Therapeutics and Clinical Risk Management 2006:2(4) 411
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acquired MRSA as an important pathogen, the addition of
vancomycin, linezolid, or some other agent with good
activity against MRSA should be considered for community-
acquired infections in which S. aureus is a suspected
pathogen.
The use of broad-spectrum antibiotics for the initial
treatment of cSSTIs has been addressed in recent practice
guidelines from the Infectious Diseases Society of America
(Lipsky et al 2004; Stevens et al 2005). Broad-spectrum
agents which provide good activity against Gram-positive
aerobes, Gram-negative aerobes, and anaerobes have been
recommended as appropriate initial choices for a variety of
cSSTIs including complicated cellulitis, severe diabetic foot
infections, surgical wound infections, infections in
immunocompromised hosts, severe animal or human bite
wounds, and necrotizing infections (Lipsky et al 2004;
Stevens et al 2005). There are currently a number of agents
that could potentially be appropriate for use in these types
of infections. β-Lactam/β-lactamase inhibitor combinations
such as piperacillin/tazobactam have been extensively used
for these indications due to their favorable spectrum of
activity and proven efficacy in a wide variety of infection
types (Tan et al 1993; Tassler et al 1993; Lipsky et al 2004,
2005). The new glycylcycline-class drug, tigecycline, has
also been shown to have good efficacy in the treatment of
cSSTIs and was approved in the US for this indication in
June 2005 (Breedt et al 2005; Wilcox 2005). Carbapenems
such as imipenem/cilastatin and, more recently, ertapenem
have also been shown to be very effective in the initial
treatment of severe cSSTIs (Grayson et al 1994; Graham et
al 2002; Lipsky et al 2005). Although the carbapenems are
too broad in spectrum for routine first-line use in all types
of infections, they are particularly well suited and
recommended as appropriate agents for infections likely to
involve mixed and/or multidrug-resistant Gram-negative
pathogens such as surgical wound and other hospital-
acquired infections, severe diabetic foot infections, and
infections in immunocompromised patients (Fung et al 2003;
DiNubile and Lipsky 2004; Lipsky et al 2004; Stevens et al
2005).
Meropenem has shown excellent efficacy in controlled
clinical studies in a variety of types of moderate to severe
infections in seriously ill patients (Wiseman et al 1995; Fish
and Singletary 1997). Clinical studies directly comparing
meropenem versus imipenem/cilastatin in the treatment of
intra-abdominal, lower respiratory tract, SSTIs, urinary tract
infections, and exacerbations of chronic obstructive
pulmonary disease (COPD) generally found these two
agents to be comparable in clinical and microbiological
efficacy (Colardyn and Faulkner 1996; Garau et al 1997).
As discussed in this article, at least three clinical studies
have also shown meropenem to be comparable with
imipenem/cilastatin in the treatment of cSSTIs, one of these
being among the largest and best-designed studies of cSSTIs
ever performed (Fabian et al 2005). While meropenem and
the other carbapenems are not generally recommended for
initial treatment of all cSSTIs because their extremely broad
spectrum of activity is not necessarily required and excessive
use of these agents is undesirable, their use is appropriate
and recommended for initial treatment in certain selected
patients as previously discussed. Meropenem is an
appropriate antibiotic choice in those patients in whom use
of a carbapenem is recommended for infections involving
pathogens known to be resistant to other narrower-spectrum,
more preferred agents.
Although meropenem is indicated by the US FDA for
treatment of cSSTIs caused by P. aeruginosa, the approved
regimen of 500 mg every 8 hours may not necessarily be
the preferred regimen for empiric treatment of cSSTIs in
higher-risk patients in which P. aeruginosa is more likely
to occur, ie, hospital-acquired infections, severe diabetic foot
infections, and infections in immunocompromised patients.
As previously discussed, pharmacokinetic/pharmaco-
dynamic analyses indicate that this regimen may not be as
favorable as higher doses, ie, 1 g every 8 hours, in reliably
achieving desired pharmacodynamic targets for treatment
of P. aeruginosa infections (Kuti et al 2004; Masterton et al
2005). Additionally, although clinical studies of meropenem
in the treatment of cSSTIs were overall very favorable,
relatively few P. aeruginosa were isolated in these studies
and the overall response rate in these patients (20/26, 77%)
was somewhat lower than the overall clinical and
microbiological efficacy rates reported in these three studies
(86% to 100% and 88% to 94%, respectively) (Lami et al
1991; Nichols et al 1995; Fabian et al 2005). These findings,
together with considerations regarding potential alterations
in drug pharmacokinetics and tissue penetration, increasing
P. aeruginosa resistance, and potential differences in local
and institutional susceptibility patterns, strongly suggest
that the use of higher daily doses of meropenem may be
more prudent when P. aeruginosa is suspected or until
specific susceptibilities can be determined in documented
strains.
In addition to meropenem’s favorable spectrum of
activity and proven clinical efficacy, meropenem is also well
tolerated and has few serious toxicities associated with itsTherapeutics and Clinical Risk Management 2006:2(4) 412
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use (Wiseman et al 1995; Fish and Singletary 1997; Norrby
and Gildon 1999). Although carbapenems have been
associated with seizures and other central nervous system
(CNS) toxicities, the rate of meropenem-associated CNS
toxicity appears to be less than that of imipenem/cilastatin
and probably similar to ertapenem (Wiseman et al 1995;
Fish and Singletary 1997; Norrby and Gildon 1999; Teppler
et al 2004). The incidence of seizures during meropenem
therapy is very low and appears to be 0.05% to 0.08% (Fish
and Singletary 1997; Norrby and Gildon 1999). This
potential difference in CNS toxicities between meropenem
and imipenem/cilastatin may be most relevant in higher-
risk patients such as those with head trauma, seizure
disorders, or other underlying CNS pathology. The overall
safety and tolerability of meropenem appears to be similar
to other carbapenems (Fish and Singletary 1997; Norrby
and Gildon 1999).
The average wholesale price (AWP) of meropenem and
other very broad-spectrum agents which are currently used
as monotherapy for the treatment of cSSTIs are shown in
Table 5 (Red Book 2005). Prices shown are based on a 7-
day course of therapy at FDA-approved doses of the
respective drugs in patients with good renal function.
Although meropenem is most easily compared against other
carbapenems, piperacillin/tazobactam and tigecycline are
also appropriate for treatment of certain cSSTIs and could
potentially be used as alternatives to carbapenems in many
patients (Fung et al 2003; Lipsky et al 2004; Breedt et al
2005; Stevens et al 2005; Wilcox 2005). Although ertapenem
and tigecycline have poor activity against P. aeruginosa and
are not strictly interchangeable with meropenem for all
infections, ertapenem does offer potential cost advantages
in the treatment of those infections for which it is appropriate
(eg, when P. aeruginosa is not a likely pathogen). Compared
with imipenem/cilastatin, a drug which is quite similar to
meropenem in terms of activity and clinical efficacy,
meropenem may in fact be more cost-effective. However,
actual costs at individual institutions will vary considerably
according to specific contract pricing agreements and costs
within countries outside of the US. The selection of one
agent over another may very well depend on prices
available to the specific institution. Local antibiograms
are also important to consider in the selection of a specific
agent.
Meropenem possesses many favorable qualities and
some possible advantages relative to other agents which are
commonly used in the treatment of cSSTIs. These
advantages may include good activity against pathogens
(particularly Gram-negative aerobes) with increasing
resistance to cephalosporins and extended-spectrum
penicillins; the ability to effectively treat many cSSTIs with
a single-drug regimen rather than a combination of agents
in order to provide adequate coverage of suspected or
documented pathogens; incomplete cross-resistance with
imipenem/cilastatin and slightly greater activity against P.
aeruginosa; potentially decreased CNS toxicity compared
with imipenem/cilastatin; and potential cost advantages.
Conversely, potential disadvantages of meropenem use
include an excessively broad spectrum of activity for
treatment of many cSSTIs in which P. aeruginosa,
anaerobes, and/or multidrug-resistant pathogens are not
likely to be present; a broad spectrum of activity which may
increase selective pressure for development of resistance
among organisms such as P. aeruginosa; the need for
addition of another agent when MRSA is possibly present
in community-acquired infections; the need for three-times-
daily dosing; and potentially higher costs relative to some
alternative agents. Based on available data, meropenem
should be considered relatively interchangeable with
imipenem/cilastatin for treatment of cSSTIs and would be
preferred over ertapenem for certain patients who are at high
risk of infection with P. aeruginosa. Meropenem is an
Table 5 Approximate treatment costs for a 7-day course of therapy with selected agents in the treatment of complicated skin and soft tissue
infection
Drug US trade name and manufacturer Dosing regimen Cost
Carbapenems
Meropenem Merrem®; AstraZeneca, Wilmington, Delaware, USA 500 mg every 8 hours $630
Imipenem/cilastatin Primaxin®; Merck & Co., Whitehouse Station, New Jersey, USA 500 mg every 8 hours $722
Ertapenem Invanz
®; Merck & Co., Whitehouse Station, New Jersey, USA 1 g every 24 hours $360
Other agents
Piperacillin/tazobactam Zosyn
®; Wyeth Pharmaceuticals, Philadelphia, Pennsylvania, USA 3.375 g every 6 hours $482
Tigecycline Tygacil
™; Wyeth Pharmaceuticals, Philadelphia, Pennsylvania, USA 50 mg every 12 hours 
a $735
Note: Figures are based on 2005 Average Wholesale Price (AWP) in the US and reflect drug acquisition costs only (Red Book 2005); 
a After an initial loading dose of
100 mg.Therapeutics and Clinical Risk Management 2006:2(4) 413
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effective and safe agent for treatment of cSSTIs for which
carbapenems are deemed appropriate.
Summary
Meropenem is a broad-spectrum carbapenem antibiotic with
excellent activity against many aerobic Gram-positive,
aerobic Gram-negative, and anaerobic organisms commonly
associated with cSSTIs. At least three clinical studies,
including one of the largest prospective, randomized,
double-blind studies of cSSTIs yet conducted, have shown
that meropenem is comparable in clinical efficacy with
imipenem/cilastatin and is well tolerated in the treatment of
these infections. Carbapenems are currently recommended
as appropriate agents in the initial treatment of certain types
of cSSTIs including those likely to involve mixed and/or
multidrug-resistant pathogens, ie, surgical wound and other
hospital-acquired infections, severe diabetic foot infections,
and infections in immunocompromised patients. When used
for appropriate types of cSSTIs in carefully selected patients,
and with the addition of a second agent for coverage of
MRSA when appropriate, meropenem is an effective and
viable alternative for monotherapy of these challenging
infections. The regimen of meropenem 500 mg every 8 hours
is appropriate for the treatment of infections caused by most
pathogens. However, this author recommends the use of
higher doses (ie, 1 g every 8 hours) for empiric treatment of
patients at higher risk of infection with P. aeruginosa or
when this specific pathogen is actually documented to be
present.
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